Insight Molecular Diagnostics Inc. (IMDX)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $70.03M
Last updated: Nov 17, 2026 at 11:06 AM ET
Insight Molecular Diagnostics Inc. (IMDX) Competitors
The companies most similar to Insight Molecular Diagnostics are Precipio (PRPO), Exagen (XGN) and Cardiff Oncology (CRDF). By market cap, Insight Molecular Diagnostics ranks 8th of the 13 companies on this page; CareDx (CDNA) is the largest at $4.09B.
Peer Comparison
IMDX's ROIC of 197.8% is above the peer median of -23.3%, and its revenue growth of -53.9% is below the median of 7.6%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Insight Molecular Diagnostics (IMDX) | $70.03M | N/A | 40.9x | 0.0% | 197.8% | -53.9% | 0.00% |
| Precipio Inc (PRPO) | $39.68M | N/A | 1.3x | -4.1% | -5.7% | 8.3% | 0.00% |
| Exagen Inc (XGN) | $105.37M | N/A | 1.3x | -25.1% | -40.4% | 6.8% | 0.00% |
| Cardiff Oncology Inc (CRDF) | $56.49M | N/A | 115.5x | 0.0% | N/A | -14.1% | 0.00% |
| Oncolytics Biotech Inc (ONCY) | $48.51M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Champions Oncology Inc (CSBR) | $65.49M | N/A | 1.0x | -1.9% | N/A | 8.8% | 0.00% |
| CareDx Inc (CDNA) | $4.09B | 48.2x | 6.4x | 25.9% | N/A | 39.3% | 0.00% |
| OnKure Therapeutics, Inc. (OKUR) | $108.33M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Veracyte Inc (VCYT) | $1.96B | 13.3x | 3.3x | 21.8% | 8.2% | 15.1% | 0.00% |
| Opko Health Inc (OPK) | $1.25B | N/A | 2.4x | -22.6% | -6.2% | 15.9% | 0.00% |
| Coherus BioSciences Inc (CHRS) | $81.21M | N/A | 1.5x | -253.4% | -144.8% | 23.4% | 0.00% |
| Coya Therapeutics, Inc. Common Stock (COYA) | $73.42M | N/A | 15.0x | 0.0% | N/A | -93.4% | 0.00% |
| MDxHealth SA (MDXH) | $13.75M | N/A | N/A | -38.3% | -40.5% | -17.2% | 0.00% |
| Peer median | $77.32M | 30.8x | 2.4x | -0.9% | -23.3% | 7.6% | 0.00% |
Similar Companies
These are the 12 companies most similar to Insight Molecular Diagnostics, ranked by how closely their business, size, sector and industry match. The largest groups, 6 each of the 12, are in Biotechnology and Diagnostics & Research.
| Company | About | Peers |
|---|---|---|
| Precipio Inc (PRPO)Diagnostics & Research | Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. | PRPO competitors |
| Exagen Inc (XGN)Diagnostics & Research | Exagen Inc. develops and markets various test products based on its Cell-Bound Complement Activation Products technology under the AVISE brand name... | XGN competitors |
| Cardiff Oncology Inc (CRDF)Biotechnology | Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. | CRDF competitors |
| Oncolytics Biotech Inc (ONCY)Biotechnology | Oncolytics Biotech Inc., a developing-stage biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of cancer. | ONCY competitors |
| Champions Oncology Inc (CSBR)Biotechnology | Champions Oncology, Inc. develops and sells technology products and solutions to customize the development and use of cancer drugs in the United States. | CSBR competitors |
| CareDx Inc (CDNA)Diagnostics & Research | CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. | CDNA competitors |
| OnKure Therapeutics, Inc. (OKUR)Biotechnology | OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. | OKUR competitors |
| Veracyte Inc (VCYT)Diagnostics & Research | Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California. | VCYT competitors |
| Opko Health Inc (OPK)Diagnostics & Research | OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico... | OPK competitors |
| Coherus BioSciences Inc (CHRS)Biotechnology | Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. | CHRS competitors |
| Coya Therapeutics, Inc. Common Stock (COYA)Biotechnology | Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). | COYA competitors |
| MDxHealth SA (MDXH)Diagnostics & Research | MDxHealth SA is a prominent biotechnology company focused on precision diagnostics that enhance cancer management, particularly in prostate and bladder cancers. | MDXH competitors |
Frequently Asked Questions About IMDX
Who are Insight Molecular Diagnostics' main competitors?
The companies most similar to Insight Molecular Diagnostics include Precipio (PRPO), Exagen (XGN), Cardiff Oncology (CRDF), Oncolytics Biotech (ONCY) and Champions Oncology (CSBR), listed from the closest match.
Who is Insight Molecular Diagnostics' biggest competitor?
CareDx (CDNA) is the largest of the similar companies at $4.09B; Precipio (PRPO) is the closest match by business profile, size, sector and industry.
How does IMDX stock compare with its competitors?
IMDX's P/S is 40.9x against a peer median of 2.4x; its net margin is 0.0% against a peer median of -0.9%.
Which of Insight Molecular Diagnostics' competitors pays a higher dividend?
Insight Molecular Diagnostics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Insight Molecular Diagnostics bigger than its competitors?
No. Insight Molecular Diagnostics is 8th by market cap among the 13 companies on this page; the largest is CareDx (CDNA) at $4.09B.
IMDX pages: Overview, Earnings, Forecast, Financials, Competitors